PDA Announces Diverse 2019 Board of Directors
BETHESDA, Md., Dec. 14, 2018
BETHESDA, Md., Dec. 14, 2018 /PRNewswire-PRWeb/ -- The Parenteral Drug Association (PDA) today announced the results of its Board of Directors Election for the term beginning January 1, 2019. In the fall of 2018, PDA's 10,500 members had an opportunity to participate in the election of new directors.
The following candidates have been elected/appointed as Directors to the PDA Board of Directors for three-year terms starting Jan. 1, 2019:
- Michael Blackton, Adaptimmune
- Bettine Boltres, West Pharmaceutical Services*
- Stephan Krause, AstraZeneca Biologics
- Anil Sawant, Merck & Co.
- Melissa Seymour, Biogen
"I congratulate the new Directors and thank the many members who took the time to vote." said Richard Johnson, PDA President & CEO. "We had a high number of members vote in this year's election, and I hope to see even more members participate in the future.
"PDA's Board of Directors is one of the most diverse in the pharmaceutical industry, and it is the participation of our members in selecting the Directors that ensures this."
PDA thanks outgoing Directors Susan Schniepp and Stephan Roenninger for their many years of service to PDA.
*Filling remainder of 2-year term of board member who resigned
About PDA – Connecting People, Science and Regulation®
The Parenteral Drug Association (PDA) is the leading global provider of science, technology and regulatory information and education for the pharmaceutical and biopharmaceutical community. Founded in 1946 as a nonprofit organization, PDA is committed to developing scientifically sound, practical technical information and resources to advance science and regulation through the expertise of its 10,000 members worldwide. Go to http://www.pda.org/footer/about-pda to learn more.